Vk1 Injection "successfully won the list of 19 provincial alliance centralized procurement with the highest comprehensive score, and another product" Inosine Injection "was also selected.
Ruicheng Biomedical Technology Co., Ltd., a wholly-owned subsidiary, cooperated with Shanghai Ruijin Hospital to develop a drainage kit for the treatment of pancreatic cancer, which was registered and approved by Jiangsu Provincial Food and Drug Administration and will be listed nationwide; The production license of the subsidiary Fujian Huakang Pharmaceutical Co., Ltd. for the "Glucosamine Hydrochloride API" has been approved by the National Drug Administration, which means that this chemical plant, which has undergone several years of transformation, will successfully transform into a pharmaceutical enterprise.
Over the past 20 years since the implementation of the "August 8th Strategy", the output value of Chengyi Pharmaceutical has increased from 110 million yuan to over 700 million yuan, and the profit has increased from 10 million yuan to 162 million yuan. Gradually, it has achieved a brilliant transformation of "product innovation, motherboard listing, and cloud management", striving to build a "Chengyi territory" of the life and health industry.
Born into the Sea: Extracting Raw Materials from Shrimp and Crab Shells
The predecessor of Chengyi Pharmaceutical was Tongshan Pharmaceutical Factory in Dongtou County, founded in 1966. At that time, it was a small pharmaceutical factory for military family members. In December 1969, at the age of 19, Yan Yiyi joined the factory and became the director of the pharmaceutical factory in 1980. In March 1994, Yan Yiyi boldly launched a "public private" reform for seven years, and the enterprise entered a period of rapid growth.
Relying on the sea and living towards the sea, island pharmaceutical companies have natural resource advantages in developing marine pharmaceuticals. "Yan Yiyi said that although Dongtou, where the company is located, faced disadvantages such as inconvenient transportation, water and electricity shortages, and insufficient talent, the coastal shrimp and crab shells in Dongtou are abundant in resources. By utilizing the advantages of raw materials, chengyi Pharmaceutical's glucosamine hydrochloride is prepared by hydrolysis of chitin, which is often extracted from shrimp and crab shells, Leap to become the largest manufacturer of glucosamine hydrochloride raw material in China.
Deepening the cultivation of marine medicine has become an important direction for Chengyi's pharmaceutical industry. The article of the sea has great potential, and the company is constantly enriching the variety of marine pharmaceuticals, "said Yan Yiyi. The company also reserves multiple products mainly focused on marine pharmaceuticals, including deep-sea fish oil, lipid-lowering, blood pressure lowering, and anti-tumor drugs.
At present, Chengyi Pharmaceutical can produce over 70 varieties and nearly a hundred specifications of drugs and health foods. Its main products include glucosamine hydrochloride raw materials and preparations, tolasemide injection and capsules, gastrodin raw materials, ribavirin and azathioprine raw materials, etc. All products have passed national GMP certification, and multiple products have passed certifications from multiple countries and regions such as the US FDA, EU EMEA, Australia TGA, UK MHRA, and Mexico COFEPRIS.
On March 15, 2017, Chengyi Pharmaceutical successfully listed on the main board of the Shanghai Stock Exchange, becoming the "first stock" in the Wenzhou pharmaceutical industry.
Science and Technology Innovation for Prosperity: Opening a Development Door
Entering the 105 production workshop of Chengyi Pharmaceutical, there are 5 production lines set up in the vast workshop. From the production of drugs to the packaging of capsules, plate making, packaging, packaging, and transportation to the warehouse, all operations are mechanized. The staff are monitoring the machine operation on the side, in order to discover and solve problems in the first time.
In terms of technological innovation, Chengyi Pharmaceutical has invested heavily in attracting authoritative experts such as domestic academicians, opening a door for high-quality development. In the pharmaceutical industry, the phenomenon of residual liquid from the injection needle sticking to the neck wall of ampoules during the filling process and being carbonized at high temperature is known as "coke head", which causes significant waste in the pharmaceutical production process. In response, Yan Yiyi was determined to overcome this problem and found a solution under the guidance of experts, ultimately achieving the "miracle" of continuous production of 10% glucose solution for 2 days without any burning.
After going public, Chengyi Pharmaceutical will invest about 5% of its annual operating revenue in research and development, which is higher than the industry average in the province. In 2020, their 0.75 grams of glucosamine hydrochloride capsules won the first place in the national centralized procurement bidding for the third batch of drugs. Nowadays, Chengyi Pharmaceutical has become the "industry leader" of this product with its "top sales volume in the country". Yan Yiyi said that Chengyi Pharmaceutical has continuously focused its product research and development direction on new products such as marine drugs, elderly medication, and anti-tumor drugs. It has established the first academician expert workstation in Dongtou, Chengyi Pharmaceutical Big Health Research Institute, and other fields, making scientific research a driving force for the sustainable development of the enterprise.
In June 2018, with the company's marketing center, technology development center, and securities affairs center settling in Shanghai Hongqiao Fuli Center, Chengyi Pharmaceutical took a substantial step from "sea" to Shanghai. After the three major centers settled in Shanghai, Chengyi Pharmaceutical attracted more pharmaceutical commercial companies to join and made greater strides in drug research and development.
Two Strong and One Big: Striving for a Double Hundred Development Strategy
For the past 20 years, Chengyi Pharmaceutical has leveraged its advantages in mountain and sea resources, vigorously developed the marine economy, and promoted the development of underdeveloped areas; At the same time, we will accelerate the construction of advanced manufacturing bases and build intelligent factories that are informationized, intelligent, digitized, and standardized. We are at the forefront of promoting new industrialization in the province and have also been rated as a provincial-level cloud benchmark enterprise and a provincial-level digital workshop.
Standing at a new starting point, Chengyi Pharmaceutical will focus on the three major development directions of "marine medicine, biopharmaceuticals, traditional Chinese medicine, and the big health industry" and the "100 billion market value, 100 year Chengyi" double goal, accelerate mergers and acquisitions, seize strategic heights, empower enterprises with new value, and achieve collectivization and high-quality development.
At the same time, we will accelerate the implementation of the "two strong and one large" strategy, strengthen the ammonia sugar industry and fish oil industry, and expand the health industry. The "Two Strong and One Large" strategy is a new exploration and practice made under the guidance of the "August 8th Strategy", which has achieved phased results in the development of marine biopharmaceuticals and the big health industry.
Sincerely reaching the world and benefiting people's livelihoods is the original intention of Chengyi Pharmaceutical's naming, and it is also one of the winning strategies for enterprises to establish themselves in the market and achieve results over the years. Under the guidance of the "August 8th Strategy", chengyi Pharmaceutical is embarking on a path of high-quality development, constantly composing a new chapter of "common prosperity" and "innovative development".
Translated from: Temperature News
Reprinted on: November 24, 2023